I. A. Alexandrov

I. A. Alexandrov

Auto-generated profile, based on publicly available information

I. A. Alexandrov

Center for Expertise and Quality Control of Medical Care

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2023 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
IZI. A. Zheleznyakova
I. A. Zheleznyakova
OVO. A. Volkova
O. A. Volkova
DFD. V. Fedyaev
D. V. Fedyaev
AZA. V. Zuev
A. V. Zuev
OPO. S. Plakhotnik
O. S. Plakhotnik
VOV. V. Omelyanovskiy
V. V. Omelyanovskiy
Background. The implementation of individual methods of high-tech medical care (HTMC) with methods of specialized medical care within the framework of a phased transition to payment methods by diagnostic-related groups (DRGs), on the one hand, significantly expanded the availability of HTMC methods for the population. Still, it created a situation with duplication of individual treatment methods in the list of HTMC types and DRGs. Amendments to the Order of the Ministry of Health of the Russian Federation (MH RF) of August 1, 2017 No. 484n, regulating the revision of HTMC types list in terms of excluding treatment methods and (or) HTMC types in case of their duplication in the context of HTMC groups and/or DRGs, marked the beginning of large-scale work in this area and required methodological ensuring the processes of forming HTMC types list, including in terms of its revision.Objective: development of a methodological approach to the formation of HTMC types list (using the example of the list for 2023). Material and methods. An analysis of legal documents regulating the HTMC availability in the Russian Federation was carried out, including the list of medical services approved by the Order of the MH RF of October 13, 2017 No. 804n, clinical recommendations for certain nosological entities, the International Classification of Diseases (10th revision), methodological recommendations on ways to pay for medical care at the expense of the compulsory health insurance (CHI) and appendices to them (decoders of DRGs for payment of medical care provided in inpatient and daytime hospital conditions), posted on the official website of the Federal CHI Fund. The frequency of the use of certain HTMC methods and DRGs was analyzed on the basis of impersonalized information from the database of registers of bills for specialized medical care, including HTMC for 2021–2022.Results. A methodological approach to the revision of HTMC types list was developed. It included its primary analysis, expert discussion of the obtained results, consideration by the Interdepartmental Council of the MH RF of proposals agreed with experts on each HTMC method submitted for discussion, followed by a decision on the appropriateness of the proposed changes, and recalculation of the standard of financial costs for HTMC and/or basic tariff for DRGs.Conclusion. The proposed methodological approach makes it possible to unify the process of revising the HTMC types list, including the exclusion of duplicate treatment methods and/or HTMC types in the sections of HTMC list types and/or in DRGs, as well as treatment methods missing in clinical recommendations, etc. in order to bring the HTMC types list in accordance with legal documents regulating the provision of medical care in the Russian Federation.

23 April 2024 in Medical Technologies. Assessment and Choice
Verified
Journal Article
Closed access
IZI.A. Zheleznyakova
I.A. Zheleznyakova
ERE.I. Rumyantseva
E.I. Rumyantseva
OVO.A. Volkova
O.A. Volkova
TAT.S. Aviaeva
T.S. Aviaeva
MSM.A. Sdvizhkova
M.A. Sdvizhkova
VOV.V. Omelyanovskiy
V.V. Omelyanovskiy
Objective. Modeling of annual cost of supportive therapy for malignant neoplasms in accordance with the guidelines of the All-Russian public organization “Russian Society of Clinical Oncology” (RUSSCO). Material and methods. The main material for modelling the cost of treatment were drug regimens presented in the RUSSCO guidelines for the following complications: chronic viral hepatitis B, hormone-mediated side effects, bone tissue pathology, immune-mediated side effects, mucositis, infusion reactions, thromboembolic complications, chronic pain syndrome, anorexia-cachexia syndrome, as well as enzyme replacement therapy for pancreatic cancer and nutritional support. To calculate population receiving anticancer drug therapy, we used data on medical billing registry database (2022). This database contains information on the number of completed cases of anticancer drug therapy and the number of appropriate patients. During the modeling, we hypothetically divided financing depending on the profiles of medical care and sources of funding. Results. The most expensive cases (87.2% of overall requirement) are treatment of bone lesions (5.532.288.615.94 rubles), thromboembolic complications (5.973.880.025.31 rubles), chronic pain syndrome (6.309.163.258.86 rubles) and nutritional support (7.009.301.585.00 rubles). Approximately 75% of the estimated funding is for «oncology» profile, i.e. treatment of complications will take place during chemotherapy period. In the current model, 47% of funding goes from the state programs of free drug supply, 28% from compulsory medical insurance to cover stay at the day and 24-hour hospitals, 23% from personal patients’ expenses. Conclusion. Modeling of supportive cancer therapy cost can underlie changes in medical care payment system.

23 April 2024 in Medical Technologies. Assessment and Choice
Verified
Journal Article
Closed access
IZI.A. Zheleznyakova
I.A. Zheleznyakova
ERE.I. Rumyantseva
E.I. Rumyantseva
OPO.S. Plakhotnik
O.S. Plakhotnik
IAI.A. Alexandrov
I.A. Alexandrov
TVT.S. Vakhrusheva
T.S. Vakhrusheva
VOV.V. Omelyanovskiy
V.V. Omelyanovskiy
Objective. To assess the cost of supportive drug therapy for 10 complications of malignant neoplasms according to the recommendations of the Russian Public Organization «Russian Society of Clinical Oncology» (RUSSCO). Material and methods. Considering the RUSSCO recommendations, we estimated drug therapy regimens for the following complications: anemia, hepatotoxicity, dermatological reactions, cardiovascular toxicity, neurological complications, nephrotoxicity, effects of extravasation, febrile neutropenia, nausea and vomiting, central venous access. To estimate the population requiring supportive therapy, we used data from registers of medical care bills for 2022. These reports contain information on the number of completed cases of antitumor drug therapy and the number of patients who received treatment. Literature data on the incidence of the above-mentioned complications were also used. Results. The largest financial costs (63.8% of all complications) were observed for the treatment of anemia (4 721 896 721.06 rubbles), hepatotoxicity (3 545 843 422.82 rubbles) and consequences of extravasation (2 388 137 692.57 rubbles). The oncology profile accounts for 66% of the estimated funding within this model. In the current model, 34% of the need is for preferential drug provision, 37% is additional need for compulsory medical insurance to finance the added cost of hospital-stay in a day hospital and 31% in a 24-hour hospital. Conclusion. These findings complement the previously published results for other complications presented in the RUSSCO recommendations. Calculation methodology and appropriate data can underlie further improvement of financing of supportive cancer therapy.